STOCK TITAN
  1. Home
  2. News
  3. IKNA

Ikena Oncology Inc - IKNA STOCK NEWS

Welcome to our dedicated news page for Ikena Oncology (Ticker: IKNA), a resource for investors and traders seeking the latest updates and insights on Ikena Oncology.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ikena Oncology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ikena Oncology's position in the market.

News
Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum
Rhea-AI Summary
Ikena Oncology to present at Stifel 2024 Targeted Oncology Forum, offering a corporate overview and one-on-one investor meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
conferences
-
News
Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Ikena Oncology, Inc. (Nasdaq: IKNA) announces positive clinical updates for IK-930 and IK-595, with strong financial results for 2023. IK-930's optimized formulation shows promising results in EHE and mesothelioma patients, with Orphan Drug Designation received. IK-595 Phase 1 study progresses in patients with RAS and RAF mutant cancers. The Company appoints a new Chief Medical Officer and focuses on core clinical programs. Financially, Ikena reports a cash position of $175.5 million, sufficient until 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.79%
Tags
earnings
-
News
Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference
Rhea-AI Summary
Ikena Oncology to participate in targeted oncology panel at TD Cowen 44th Annual Health Care Conference, with CEO Mark Manfredi presenting on March 5, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
conferences
News
Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer
Rhea-AI Summary
Ikena Oncology, Inc. announces the appointment of Dr. Caroline Germa as Chief Medical Officer and the resignation of Dr. Sergio Santillana. Dr. Germa brings over 25 years of pharmaceutical experience and will lead the clinical development strategy for the company's targeted oncology programs, IK-930 and IK-595. Her appointment emphasizes Ikena's commitment to innovation in the oncology space.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
News
Ikena Oncology Outlines Key Priorities and Provides Corporate Updates
Rhea-AI Summary
Ikena Oncology, Inc. provides an organizational update outlining key objectives toward advancing the development of its lead targeted oncology assets, IK-930 and IK-595. The company is focused on driving IK-930 and IK-595 forward to deliver interpretable and clear data reads, maximizing impact, and driving advancements in patient-directed treatments for cancer. The company also announced an organizational streamlining that allows for the reallocation of resources from exploratory research and discovery towards the ongoing targeted oncology clinical programs. With approximately $175 million in cash and cash equivalents as of December 31, 2023, the company's runway is extended into the second half of 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.32%
Tags
none
-
News
Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Ikena Oncology, Inc. (Nasdaq: IKNA) announced favorable safety profile in dose escalation for IK-930, showing minimal treatment-related proteinuria without dose reductions or interruptions. Encouraging clinical activity and tumor shrinkage in patients with epithelioid hemangioendothelioma (EHE) were observed. Additional clinical data update planned for second half of 2024. Pipeline build continues with clinical startup for IK-595 anticipated by end of 2023, with cash runway into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-67.8%
Tags
earnings clinical trial
News
Ikena Oncology to Present at Multiple November 2023 Investor Conferences
Rhea-AI Summary
Ikena Oncology, Inc. (Nasdaq: IKNA) will participate in three investor conferences in November, presenting at the Stifel Healthcare Conference on November 14, Jefferies London Healthcare Conference on November 14-16, and Piper Sandler 35th Annual Healthcare Conference on November 28-30.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.04%
Tags
conferences
-
News
Ikena Oncology to Participate in September 2023 Investor Conferences
Rhea-AI Summary
Ikena Oncology, Inc. (Nasdaq: IKNA) announces participation in investor conferences in NY. Fireside chat on Sep 11 at 3:35pm ET. Webcast available on their website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.9%
Tags
conferences
-
News
Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update
Rhea-AI Summary
Ikena Oncology, Inc. (Nasdaq: IKNA) announced financial results for the quarter ended June 30, 2023, including a strong financial position, progress in clinical trials for IK-930 and IK-595, and the acquisition of Pionyr Immunotherapeutics Inc. The company believes its cash at hand will be sufficient to meet its operating requirements into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.1%
Tags
earnings
News
Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction
Rhea-AI Summary
Ikena acquires Pionyr in all-stock transaction, receiving $43 million in net cash. The capital will accelerate development of targeted oncology pipeline. Initial clinical data from IK-930 expected later this year. Gilead Sciences among new shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.51%
Tags
acquisition
Stock IKNA logo
Ikena Oncology Inc

Nasdaq:IKNA

IKNA Rankings

#4589 Ranked by Market Cap
#614 Ranked by Stock Gains
N/A Ranked by Dividends

IKNA Stock Data

64.18M
17.90M
7%
100.01%
2.59%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
Boston

About IKNA

ikena oncology (formerly kyn therapeutics) is a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven therapies for cancer patients, by understanding what drives their disease. we are advancing multiple development and discovery programs: an ep4 receptor antagonist; an ahr antagonist; a kynurenine-degrading enzyme; a discovery-stage program targeting the hippo signaling pathway; and a discovery-stage program against an undisclosed target.. in addition to raising capital from top tier investors orbimed advisors and atlas venture, we have entered into a global strategic collaboration with celgene on the ahr antagonist and kynase programs. “at ikena, we begin with the end in mind. we focus on subgroups of patients based on their biomarker profiles who will most benefit from our immunotherapy and tumor cell-targeted drug candidates, ensuring that we can bring the right drug to the right patient battling cancer.” mark manfredi, chief executi